Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcome...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2026-03-01
Serier:	Cancer Medicine
Fag:	common EGFR mutation dacomitinib epidermal growth factor receptor mutation non‐small cell lung cancer (NSCLC) tyrosine kinase inhibitor
Online adgang:	https://doi.org/10.1002/cam4.71659
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!